Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Hexosediphosphates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1983

Cyclic AMP and fructose-2,6-bisphosphate stimulated in vitro phosphorylation of yeast fructose-1,6-bisphosphatase.

Phosphorylation of purified yeast fructose-1,6-bisphosphatase was studied using purified preparations from yeast of two different cyclic AMP-independent protein kinases and a cyclic AMP-dependent protein kinase. Incorporation of 32P into fructose-1,6-bisphosphatase could be demonstrated only with the cyclic AMP-dependent protein kinase. Phosphorylation of fructose-1,6-bisphosphatase was stimulated by 3 microM fructose-2,6-bisphosphate and inhibited by 1 mM 5'-AMP.

Cyclic AMP↗
PubMed1983

Effect of fructose 1,6-bisphosphate on the activity of liver pyruvate kinase after limited proteolysis with cathepsin B.

Treatment of rat liver-type pyruvate kinase with rabbit liver cathepsin B at pH 7.0 caused loss of activity in the standard assay with 0.6 mM of phosphoenolpyruvate. The modified enzyme exhibited about 10% of the original activity when assayed with 2.0 mM of the substrate. No detectable change in the subunit molecular weight of the enzyme occurred during inactivation. On addition of 4 microM fructose 1,6-bisphosphate the activity of the treated enzyme was restored to that of the original enzyme. Limited proteolysis of the enzyme by cathepsin B appears to enhance the requirement for the positive effector, fructose 1,6-bisphosphate.

Animals↗
PubMed1983

The role of fructose 2,6-bisphosphate in the long-term control of phosphofructokinase in rat liver.

The phosphofructokinase stabilizing factor, believed to be a peptide of molecular weight 3,800 (Dunaway G.A. and Segal H.L., 1976, J. Biol. Chem. 251, 2323-2329), shares many chemical and biological properties with fructose 2,6-bisphosphate. It co-migrated with it upon gel filtration in the molecular weight range 300-400 or 3,000-4,000 depending upon the ionic strength of the solution. Fructose 2,6-bisphosphate is the most potent phosphofructokinase stabilizing agent present in the liver of a fed rat. Its disappearance during fasting and diabetes could account for the faster rate of degradation of phosphofructokinase reported to occur under these conditions. The effect of starvation to decrease by 60% the phosphofructokinase content of the liver is, however, for its greatest part, related to a non-specific decrease in liver mass.

Animals↗
PubMed1983

Perinatal changes of fructose 2,6-bisphosphate in the rat liver.

In order to investigate a possible regulatory role of fructose 2,6-bisphosphate in early developmental stages, where profound changes in the carbohydrate metabolism are known to occur, this effector was estimated in fetal and postnatal rat liver. Polyphasic changes of the hepatic fructose 2,6-bisphosphate levels were found, which could be correlated to alterations in the glucose metabolism. A minimum in the hepatic fructose 2,6-bisphosphate level at the -3rd day coincides with the initiation of glycogen synthesis and its increase two hours after birth concurs with glycogen mobilization.

Aging↗
PubMed1984

Regulation of glucose metabolism in rat adrenal gland in alloxan-diabetes: the possible role of fructose 2,6-bisphosphate.

The level of fructose 2,6-bisphosphate is markedly decreased in the rat V.renal gland in diabetes, falling to 23% of the control value. There is parallel decrease in the flux of 14C-labelled glucose through the glycolytic route and tricarboxylic acid cycle. Only minimal changes in hexokinase (EC 2.7.1.1.), a 22% decrease in Type I hexokinase of the soluble fraction, were observed, highlighting the probable significant involvement of fructose 2,6-bisphosphate in the regulation of glycolysis in the adrenal. In contrast, there was evidence for a marked rise in the flux of glucose through the pentose phosphate pathway, which may be linked to enhanced corticoid synthesis in the diabetic state.

Adrenal Glands↗
PubMed1984

Inhibition of Escherichia coli fructose-1,6-bisphosphatase by fructose 2,6-bisphosphate.

Fructose 2,6-bisphosphate, a potent inhibitor of fructose-1,6-bisphosphatases, was found to be an inhibitor of the Escherichia coli enzyme. The substrate saturation curves in the presence of inhibitor were sigmoidal and the inhibition was much stronger at low than at high substrate concentrations. At a substrate concentration of 20 microM, 50% inhibition was observed at 4.8 microM fructose 2,6-bisphosphate. Escherichia coli fructose-1,6-bisphosphatase was inhibited by AMP (Ki = 16 microM) and phosphoenolpyruvate caused release of AMP inhibition. However, neither AMP inhibition nor its release by phosphoenolpyruvate was affected by the presence of fructose 2,6-bisphosphate. The results obtained, together with previous observations, provide further evidence for the fructose 2,6-bisphosphate - fructose-1,6-bisphosphatase active site interaction.

Adenosine Monophosphate↗
PubMed1984

Fructose 2,6-bisphosphate, a potent regulator of carbohydrate metabolism, inhibits trehalose phosphorylase from protist Euglena gracilis.

Partially purified trehalose phosphorylase (EC 2.4.1.64) from Euglena gracilis SM-ZK was inhibited by fructose 2,6-bisphosphate in both synthetic and degradative directions. Ki value for trehalose phosphorolysis was 1.2 microM and that for trehalose synthesis was 0.5 microM. Functions of fructose 2,6-bisphosphate in Euglena, particularly in the regulative mechanism of the two reserve carbohydrates, paramylon and trehalose, are discussed.

Adenine Nucleotides↗
PubMed1984

Pentobarbital-anesthesia decreases fructose 2,6-bisphosphate levels in rat liver.

Fructose 2,6-bisphosphate levels were assayed in freeze-clamped livers of anesthesized rats. All doses of pentobarbital that were effective in anesthesizing the rats caused a significant decrease in fructose 2,6-bisphosphate levels. Injection of pentobarbital also resulted in decreased 6-phosphofructo 2-kinase activity and increased fructose 2,6-bisphosphatase activity measured in dialyzed (NH4)2SO4-treated liver extracts but with no change in pyruvate kinase activity. It was concluded that the anesthesia-induced decrease in fructose 2,6-bisphosphate levels results at least in part from increased phosphorylation of 6-phosphofructo 2-kinase/fructose 2,6-bisphosphatase.

Anesthesia, General↗
PubMed1984

Metabolite-induced activation of hepatic phosphofructokinase.

Hepatic phosphofructokinase, isolated in a medium containing 100 mM (NH4)2SO4, can be activated by ATP. This metabolite-induced activation was investigated in view of the suggestion that it is related to phosphorylation of phosphofructokinase. The results obtained do not support this interpretation. Inhibitors of protein phosphatases (NaF) and kinases (the Mg++-chelator, ethylene diamine tetraacetic acid) did not affect the recovery of phosphofructokinase. In contrast, media of high ionic strength reduced the phosphofructokinase activity and rendered the enzyme sensitive to ATP-induced activation. Activation was also induced by other known effectors of phosphofructokinase (nucleoside triphosphates, fructose bisphosphates) and was not dependent on Mg++-ions. It is suggested that activation represents ligand-induced reversal of the inactivation of phosphofructokinase which occurs at high ionic strength. The differential sensitivity of phosphofructokinase from fed or starved animals to inactivation and reactivation is discussed.

Adenosine Triphosphate↗
PubMed1984

Decreases in hepatic fructose-2,6-bisphosphate level and fructose-6-phosphate,2-kinase activity in diabetic mice: a close relationship to the development of ketosis.

Hyperglycemic mice with streptozotocin diabetes were divided into two groups according to the presence or absence of ketosis. No difference in blood glucose level between two groups was observed in this experiment. However, hepatic fructose-2,6-P2 level and fructose-6-P,2-kinase activity were decreased only in ketotic diabetic mice. Similar decreases in those indices were observed in 48-h starved normal mice. In ketotic diabetes, insulinization for 24 h was required to normalize fructose-2,6-P2 level and fructose-6-P,2-kinase activity, while glucose administration normalized altered fructose-2,6-P2 metabolism in starvation only in 30 min. Hepatic cyclic AMP was increased neither in ketotic nor in non-ketotic diabetic mice. These results indicate that the decrease in hepatic fructose-2,6-P2 level in diabetes is apparently related to the occurrence of ketosis, but not to hyperglycemia. The mechanisms of the decrease in fructose-6-P,2-kinase activity in ketotic diabetes and starvation are discussed.

Animals↗